Original Research Article

Study of vitamin B12 deficiency in chronic kidney disease

Vinod Ananda Dandge*, Dhruv Variya

INTRODUCTION

Patients affected by CKD have a shorter life expectancy than those with normal renal function, primarily due to the dramatic increase in cardiovascular mortality. Chronic Haemodialysis treatment is associated with a 10-50-fold higher risk of premature death than in the general population, and cardiovascular disease (CVD) represents the leading cause of death in haemodialysis patients. Nevertheless, such increased cardiovascular risk is present since earlier stages of CKD.

Hypertension, dyslipidemia and diabetes mellitus have been proven to be poor predictors of cardiovascular risk in this population. Therefore, there has been growing attention on non-traditional cardiovascular risk factors, in particular oxidative stress, endothelial dysfunction, chronic inflammation, vascular calcification, Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) and hyperhomocysteinemia. Furthermore, the high
prevalence of hyperhomocysteinemia in patients with CKD has increased interest in speculating the role for hyperhomocysteinemia as a risk factor for the progression of CKD. The role of folic acid and vitamin B12 role is well recognized, as they are not only essential cofactors for homocysteine metabolism, but their homeostasis disruption may be related directly to cardiovascular risk and CKD progression. A serum B12 above 300 pg/mL is interpreted as normal. Patient’s with B12 levels between 200 and 300 pg/mL are considered borderline. Patients with B12 levels below 200 pg/mL are considered deficient. However; a low serum B12 level does not determine the etiology of the deficiency. If the etiology is uncertain, further testing should be done to investigate.

Patients with CKD have been shown to have higher homocysteine blood levels compared to the general population. It has been hypothesized that hyperhomocysteinemia in these patients may be induced by the abnormality of homocysteine metabolism in the kidneys rather than by reduced glomerular filtration rate. In fact, although free homocysteine can pass the ultrafiltration barrier due to its low molecular weight, it circulates in the blood stream mostly (about 90%) in the protein-bound form. In particular, trans sulfuration and remethylation pathways occurring in the kidney may be affected by renal disease. Stable isotope studies in Non-diabetic and diabetic patients with CKD have shown impaired metabolic clearance of homocysteine determined by dysfunction in both pathways.

In patients of CKD, several metabolic alterations, including acidosis, systemic inflammation and hormonal dysregulation, together with co morbidities and multidrug therapies, can lead to malnutrition with subsequent folic acid and vitamin B12 deficiency. In addition, anorexia, gastroparesis, slow intestinal transit or diarrhoea, increased gut mucosal permeability and gut microbioes impairment may represent worsening factors.

Vitamin B12 in the blood is primarily protein-bound. Approximately 20% of circulating B12 is bound to transcobalamin; this is the biologically active form that can be taken up into cells. Although CKD patients display increased transcobalamin levels, they show an impaired vitamin uptake of B12. Moreover, in uremic patients a functional vitamin B12 deficiency can be observed because of increased transcobalamin losses in the urine and reduced absorption in the proximal tubule. This can lead to a “paradoxical” increase in cellular homocysteine levels despite normal total B12.

On the other hand, potentially overdosage-related vitamin B12 toxicity could result exacerbated in individuals with CKD. Cyanocobalamin, the most commonly used form of B12s supplementation therapy, is indeed metabolized to active methylcobalamin, releasing small amounts of cyanide whose clearance is reduced in CKD. Under normal conditions, methylcobalamin is required to remove cyanide from the circulation through conversion to cyanocobalamin. However, in CKD patients, the reduced cyanide clearance prevents conversion of cyanocobalamin to the active form and therefore supplementation is less effective.

Patients with chronic inflammation, such as the haemodialysis population, display decreased production of transcobalamin due to impaired uptake of circulating Vit-B12 by peripheral tissues. This can determine increased synthesis of transcobalamin’s I and III that brings to further accumulation of B12 in blood. Therefore, in the context of inflammatory syndromes, despite high vitamin B12 blood levels, there is a vitamin B12 deficiency in target tissues, potentially leading to hyperhomocysteinemia and increased cardiovascular risk (Figure 2).

Administration of intravenous B-Complex vitamins is proven to be more efficient in reducing homocysteine serum levels and restoring there methylation pathway in CKD patients.

METHODS

The “Study of Vitamin B12 Deficiency in Chronic Kidney Disease” is the observational cross-sectional study done on 80 cases in SMIMER.

The present study was conducted on randomly selected cases of CKD coming to SMIMER Hospital from January 2018 to August 2019. Patients with radiology USG kidney showing changes of CKD, and S. Creatinine, S. blood urea, S. Calcium S. Phosp and urine routine showing CKD features with S. Vitamin B12 level were included. Patients history and examination, all the information regarding sociodemographic Data was collected in the predesigned, pretested and Semi structured Questionnaire by interview method by the Investigator. Participants fasting morning plasma samples were taken and Vitamin B12 was measured.

Inclusion criteria

All indoor cases willing to participate in the study, with History of CKD, admitted in Dialysis unit of SMIMER hospital were included in the study.

Exclusion criteria

- Age ≤18 years
- Strict vegetarian diets
- Vitamin-B12 deficiency anaemia due to any other etiology
- Conditions affecting small Intestine such as ileal Resection, Crohn’s Disease, celiac disease, Bacterial growth or a parasite
- Drugs like Methotrexate, Sodium Valproate, Pernicious Anaemia, Gastrectomy, Atropic Gastritis
• Autoimmune diseases, including Type 1 Diabetes, Graves’ disease

Statistical analysis

Statistical methods were descriptive and inferential statistic an analysis has been carried out in the present study. Results on continuous measurements are presented on Mean±SD (Min-Max) and results on categorical measurements are presented in Number (%).

Significance is assessed at 5% level of significance. The following assumptions on data are made. Dependent variables should be normally distributed, and samples drawn from the population should be random. Cases of the samples should be independent.

Analysis of Variance (ANOVA) has been used to find the significance of study parameters on categorical scale between two or more groups (Inter group analysis) on metric parameters. Chi-square/Fisher Exact test has been used to find the significance of study parameters on categorical scale between two or more groups.

Significant figures

Suggestive significance (p value: 0.05<p<0.10), *Moderately significant (p value: 0.01<p<0.05), **Strongly significant (p value:p<0.01)

Statistical software was the Statistical software namely SPSS15.0, Stata10.1, MedCalc9.0.1 were used for the analysis of the data and Microsoft word and Excel have been used to generate tables.

RESULTS

Table 1 shows a total of 80 cases were reported and analysed in this study. Majority of the respondents were above middle aged Between 40- 60 Years, around 61.2 % of the respondents were male and nearly 42.5% are non-working, and dependent. Nearly 77.5% cases are taken from patients residing in Surat city, which came into urban area, and 22.5% cases are from rural areas, which are mostly villages and small towns near Surat city.

Table 2 shows majority of cases had symptoms of chronic kidney disease which includes, swelling of Legs up to feet and ankles 63.7%, second most common complaint was fatigue and not feeling hungry (Severe Anorexia), which was reported in up to 46.2% of cases, besides other symptoms like itching, breathlessness, too much urine initially followed by very less urine at later stage of disease. In reference to Vitamin B12 Deficiency symptoms in CKD subjects 45% had common symptoms of tingling and numbness, burning feet, particularly at night time.

Table 1: Socio Demographic profile of subjects.

| Gender          | Frequency | %    |
|-----------------|-----------|------|
| Male            | 49        | 61.2 %|
| Female          | 31        | 38.8 %|

| Age(years)      | Frequency | %    |
|-----------------|-----------|------|
| <40             | 7         | 8.8 %|
| 40-60           | 48        | 60.0 %|
| >60             | 25        | 31.2 %|

| Residence       | Frequency | %    |
|-----------------|-----------|------|
| Rural           | 18        | 22.5 %|
| Urban           | 62        | 77.5 %|

| Occupation      | Frequency | %    |
|-----------------|-----------|------|
| Labourer        | 12        | 15   |
| Housework       | 26        | 32.5 %|
| Non-Working     | 34        | 42.5 %|
| Others          | 8         | 10   |

Table 2: Distribution of cases according to symptoms.

| Symptoms                                | Frequency | Percent |
|-----------------------------------------|-----------|---------|
| Swelling of legs (Pedal edema)          | 51        | 63.7    |
| Tingling, numbness, burning feet        | 36        | 45.0    |
| Fatigue and anorexia                    | 37        | 46.2    |

Table 3: Distribution of cases according to past history of diabetes mellitus, hypertension family h/o CKD/renal stone.

| Past history DM | Cases | %   |
|-----------------|-------|-----|
| Present         | 31    | 38.8 |
| Absent          | 49    | 61.2 |

| Past History Hypertension | Cases | %   |
|----------------------------|-------|-----|
| Present                    | 63    | 78.75 |
| Absent                     | 17    | 21.25 |

| Family History CKD | Cases | %   |
|--------------------|-------|-----|
| Present            | 4     | 5    |
| Absent             | 76    | 95   |

| Renal stone | Cases | %   |
|-------------|-------|-----|
| Present     | 12    | 15   |
| Absent      | 68    | 85   |

Around 78% subjects had Hypertension, out of which 62% patients previously had hypertension and 16% patient was developed hypertension after they diagnosed as CKD. Out of 80 cases in our study 38.8% of cases had Diabetes (28 cases Type 2 DM+ 3 cases Type 1 DM Nephropathy), with duration more than >6 Years, rest 5% cases had family history of kidney disease, (3 had Polycystic kidney disease 1 was undiagnosed family history) (Table 3).
Peripheral Blood smear examination of 58.8% patient had increased Mean corpuscular volume (MCV >100 fl)and Macrocyte (Larger than normal RBC),.....% cases had blood picture showing low platelets count, Neutrophil granulocytes with hyper segmented nuclei, Anisocytosis (increased variation in RBC size), Poikilocytosis(abnormally shaped RBC), Howell-Jolly bodies Present (Table 4).

Table 4: Distribution of cases according MCV and vitamin B12 deficiency Level/ Peripheral Blood Smear picture (Figure 1).

| MCV (>100 fl) Macrocytis | Frequency | Percent |
|--------------------------|-----------|---------|
| Raised                   | 47        | 58.8    |
| Normal                   | 33        | 41.2    |
| Platelet count reduced   |           |         |
| Present                  | 55        | 68.75   |
| Absent                   | 25        | 31.25   |
| Vitamin B12 deficiency   |           |         |
| Present                  | 47        | 58.8    |
| Absent                   | 33        | 41.2    |
| Hyper segmented, Neutrophil Anisocytosis, Poikilocytosis | Present | 27 | 33.75 |
| Absent                   | 53        | 66.25   |

It was observed that among the vitamin B12 deficient group, all cases had reduced Kidney size, shrunken kidney, while among the Vitamin B12 normal group only 25 cases had reduced Kidney size and rest 8 cases had normal Kidney size. Data reflects incidence of Vitamin B12 Increases as the size of kidney reduces (Table 5).

Table 5: Comparison of vitamin B12 deficiency with kidney size.

| Kidney size  | Deficient vit B12 | Normal vit B12 | Total |
|--------------|-------------------|----------------|-------|
|              | No. | %   | No. | %   | No. | %   |
| Reduce       | 47  | 100.0 | 25  | 75.8 | 72  | 90.0 |
| Normal       | 0   | 0    | 8   | 24.2 | 8   | 10.0 |
| Total        | 47  | 100.0 | 33  | 100.0 | 80  | 100.0 |

Table 6 shows, out of 80 cases authors studied, authors observed that incidence of vitamin B12 deficiency increases with the increase duration of CKD, cut off was kept 6 years for duration of CKD.

Table 6: Comparison of Vitamin B12 deficiency with duration of CKD.

| Duration of CKD | Deficient vit B12 | Normal vit B12 | Total |
|-----------------|-------------------|----------------|-------|
|                 | No. | %   | No. | %   | No. | %   |
| <6 years        | 20  | 42.6 | 21  | 63.6 | 41  | 51.3 |
| >6 years        | 27  | 57.4 | 12  | 36.4 | 39  | 48.8 |

DISCUSSION

In the present study it was observed that out of 80 cases, 47 cases had vitamin B12 deficiency while 33 cases did not have vitamin B12 deficiency. The incidence of CKD was more among males than in females, may be due to more incidence of Hypertension, Diabetes (Risk factor for CKD) 10ln males than females, The average Age of presentation of CKD is 40-60, as CKD is chronic disease takes time to develop full blown features of CKD. In the study 62 cases were from Urban areas than 18 cases in rural areas, it could be attributed probably due to poor living or working conditions pollution, etc.

Or incidence of Hypertension, Type 2 DM more in urban population compare to rural areas. Regarding occupation 34 cases were Non-Working, and dependent, due to frequent follow up for hemodialysis (Thrice weekly schedule) reflecting high morbidity in CKD.

In reference to vitamin B12 deficiency symptoms in CKD subjects 45% had common symptoms of tingling and numbness, burning feet, particularly at night time, there Peripheral Blood smear examination of shows decreased RBC count and haemoglobin level, 58.8% patient had increased Mean corpuscular volume (MCV >100 fl)and Macrocyte ( Larger than normal RBC),.....% cases had blood picture showing low platelets count, Neutrophil granulocytes with Hyper segmented nuclei, Anisocytosis(increased variation in RBC size), Poikilocytosis (abnormally shaped RBC), Howell-Jolly bodies.

In the present study, the mean haemoglobin of the participants in vitamin B12 deficient group was 8.62±2.125 and vitamin B12 normal group was 9.02±1.631.The association between mean haemoglobin of participants among both group was statistically insignificant.

Anemia is a common manifestation of CKD and the prevalence of anemia increases as the eGFR declines. Anaemia’s associated with a poorer quality of life and the rapid decline of renal function, as well as cardiovascular mortality.

Anemia is mainly caused by insufficient kidney EPO production and a deficiency of the available iron to support on-going erythropoiesis in CKD patients. However, several different factors including inflammation, malnutrition, and metabolic disease, have been considered to contribute to the anemia of CKD. The mean duration of CKD of the participants in vitamin B12 deficient group was 6.59±2.894 and Vitamin B12 normal group was 5.18±2.324. The association between mean duration of CKD of participants among both groups was statistically significant (p-value 0.02). It was observed that incidence of Vitamin B12 deficiency increases with the increase duration of CKD. It was also observed that
among the Vitamin B12 deficient group, all cases had reduced kidney size, shrunken kidney, while among the vitamin B12 normal group only 25 cases had reduced kidney size and rest 8 cases had normal kidney size. relatively increase incidence of vitamin B12 deficiency as the size of kidney reduces.

CONCLUSION

From the study, it is concluded that, there is high prevalence of vitamin B1 deficiency in CKD patients besides other causes of anemia. Hence, serum vitamin B12 level testing should be recommended routinely in patients with chronic kidney disease and all the treating nephrologists/physicians should anticipate the deficiency of vitamin B12 in CKD patients and take appropriate measures to prevent associated morbidity and mortality of CKD.15

ACKNOWLEDGEMENTS

Authors would like to thank Dr. Vipul Shirvastav sir, Head of Unit for his guidance, and analysis of data and helping in completion of the study.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Marti F, Vollenweider P, Marques-Vidal PM, Mooser V, Waer G, Paccaud F, et al. Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study. BMC Public Health. 2011Dec;11(1):733.
2. Soochoo M, Ahmadi SF, Qader H, Streja E, Obi Y, Moradi H, et al. Association of serum vitaminB12 and folate with mortality in incident haemodialysis patients. Nephrol Dialysis Transplanta. 2016May11;32(6):1024-32.
3. Ankar A, Kumar A. Vitamin B12 Deficiency (Cobalamin). Stat Pearls. 2019;2019.
4. Brattström L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect?. The Am J Clin Nutr. 2000 Aug 1;72(2):315-23.
5. Ermens AA, Vlasveld LT, Lindemans J. Significance of elevated cobalamin (vitamin B12) levels in blood. Clini Biochem. 2003 Nov 1;36(8):585-90.
6. Andrè E, Serraj K, Zhu J, Vermoren AJ. The pathophysiology of elevated vitamin B12 in clinical practice. QJM: Inter J Med. 2013 Jun 1;106(6):505-15.
7. Sviri S, Khalaila R, Daher S, Bayya A, Linton DM, Stav I, et al. Increased Vitamin B12 levels are associated with mortality in critically ill medical patients. Clini Nutr. 2012 Feb 1;31(1):53-9.
8. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Int Med. 2002 Jun 24;162(12):1401-8.
9. McMahon GM, Hwang SJ, Fox CS. The association between vitamin B12, albuminuria and reduced kidney function: an observational cohort study. BMC Nephrol. 2015 Feb 2;16:7.
10. Babazono T, Hanai K, Suzuki K, Kiuchi Y, Inoue A, Tanaka M, Tanaka N, Hase M, Ishii A, Iwamoto Y. Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia. 2006 Jun 1;49(6):1387-93.
11. Thomas MC, Maclsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care. 2003 Apr 1;26(4):1164-9.
12. Levey AS, De Jong PE, Coresh J, Nahas ME, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Inter. 2011 Jul 1;80(1):17-28.
13. Astor BC, Arnett DK, Brown A, Coresh J. Association of kidney function and haemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2004;43:836.
14. Ulasi II, Arodiwe EB, Ijoma CK. Left ventricular hypertrophy in African Black patients with chronic renal failure at first evaluation. Ethni Dis. 2006 Sep 1;16(4):859-64.
15. Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, Xu X, Wang X. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clini J Am Soc Nephrol. 2011 Mar 1;6(3):482-8.
16. Geneva S. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. 2011 Vitamin and Mineral Nutrition Information System. Available at: http://www. who.int/entity/vmnis/indicators/haemoglobin. pdf Accessed on 6 February 2017.

Cite this article as: Dandge VA, Variya D. Study of vitamin B12 deficiency in chronic kidney disease. Int J Adv Med 2020;7:303-7.